Zacks Research Upgrades Omnicell (NASDAQ:OMCL) to Hold

Omnicell (NASDAQ:OMCL) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

A number of other brokerages also recently issued reports on OMCL. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Finally, Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Trading Down 1.4%

Shares of OMCL stock opened at $33.88 on Monday. The business’s fifty day moving average price is $39.06 and its 200 day moving average price is $39.21. The firm has a market capitalization of $1.54 billion, a PE ratio of 40.33, a P/E/G ratio of 0.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell has a 1-year low of $29.06 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.Omnicell’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, sell-side analysts forecast that Omnicell will post 1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OMCL. Squarepoint Ops LLC raised its stake in shares of Omnicell by 80.8% during the 2nd quarter. Squarepoint Ops LLC now owns 120,419 shares of the company’s stock worth $5,000,000 after buying an additional 53,807 shares during the last quarter. Nykredit A S acquired a new stake in Omnicell in the 2nd quarter valued at about $26,000. Corient Private Wealth LP grew its stake in Omnicell by 46.7% in the 2nd quarter. Corient Private Wealth LP now owns 62,809 shares of the company’s stock valued at $2,608,000 after acquiring an additional 20,000 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Omnicell during the 2nd quarter valued at about $340,000. Finally, California State Teachers Retirement System increased its holdings in Omnicell by 4,074.3% during the 2nd quarter. California State Teachers Retirement System now owns 2,100,621 shares of the company’s stock valued at $87,218,000 after acquiring an additional 2,050,298 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.